» Articles » PMID: 22123274

Antipsychotic Drugs and the Risk of Hyperglycemia in Older Adults Without Diabetes: a Population-based Observational Study

Overview
Publisher Elsevier
Specialty Geriatrics
Date 2011 Nov 30
PMID 22123274
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To determine whether current antipsychotic use among older persons without diabetes is associated with a higher risk of hospital visits for hyperglycemia, as previous studies in this population have yielded conflicting results.

Design, Setting And Participants: A nested case-control study within a population-based cohort of persons aged 66 years or older without diabetes, who initiated antipsychotic therapy between April 1, 2002, and March 31, 2006. Cohort members were identified using health databases from Ontario, Canada, and were followed from treatment start until March 31, 2007.

Measurements: Cases were patients with a hospital visit (emergency department visit or hospital admission) for hyperglycemia. We matched each case with up to 10 controls. We compared the risk of hyperglycemia among current antipsychotic users to that of remote users (discontinued > 180 days).

Results: The cohort consisted of 44,121 subjects, mean age of 78.3 years, followed for a mean of 2.2 years. Compared to remote antipsychotic use, current treatment with any antipsychotic was associated with a significantly increased risk of hospital visits for hyperglycemia (adjusted odds ratio [aOR]: 1.52; 95% confidence interval [CI]: 1.07-2.17). The risk was elevated for both atypical (aOR: 1.44; 95% CI: 1.01-2.07) and typical (aOR: 2.86; 95% CI: 1.46-5.59) antipsychotic agents.

Conclusions: Current use of either atypical or typical antipsychotic agents was associated with a significantly increased risk of hospital visits for hyperglycemia among older persons without diabetes. These findings highlight the need for close glucose monitoring during antipsychotic therapy in older populations.

Citing Articles

Applicability of somatic monitoring instructions in clinical practice guidelines on antipsychotic drug use.

Brouwer J, Olde Hengel E, Risselada A, Van Roon E, Mulder H BMC Psychiatry. 2021; 21(1):189.

PMID: 33845804 PMC: 8042861. DOI: 10.1186/s12888-021-03162-w.


Real-World Data on the Adverse Metabolic Effects of Second-Generation Antipsychotics and Their Potential Determinants in Adult Patients: A Systematic Review of Population-Based Studies.

Bernardo M, Rico-Villademoros F, Garcia-Rizo C, Rojo R, Gomez-Huelgas R Adv Ther. 2021; 38(5):2491-2512.

PMID: 33826090 PMC: 8107077. DOI: 10.1007/s12325-021-01689-8.


History of coronary heart disease increased the mortality rate of patients with COVID-19: a nested case-control study.

Gu T, Chu Q, Yu Z, Fa B, Li A, Xu L BMJ Open. 2020; 10(9):e038976.

PMID: 32948572 PMC: 7499679. DOI: 10.1136/bmjopen-2020-038976.


Evaluation of the Impact of Corticosteroid Dose on the Incidence of Hyperglycemia in Hospitalized Patients with an Acute Exacerbation of Chronic Obstructive Pulmonary Disease.

Baker J, Pace H, Ladesich J, Simon S Hosp Pharm. 2016; 51(4):296-304.

PMID: 27303077 PMC: 4896332. DOI: 10.1310/hpj5104-296.


Atypical antipsychotic-induced metabolic disturbances in the elderly.

Guenette M, Chintoh A, Remington G, Hahn M Drugs Aging. 2014; 31(3):159-84.

PMID: 24477569 DOI: 10.1007/s40266-014-0152-x.